Is a Human Proteome Project Next?

Three dozen scientists, officials, and executives from academia, government, and business are speaking this week at a conference in McLean, Va., titled "Human Proteome Project: Genes Were Easy." This event, which is expected to draw at least 400 other participants, is the first sizable public meeting devoted to the possibility and advisability of a proteome project, according to organizer Chris Spivey, a conference director at Cambridge Healthtech Institute in Newton Upper Falls, Mass. The Vir

Written byDouglas Steinberg
| 11 min read

Register for free to listen to this article
Listen with Speechify
0:00
11:00
Share

The Virginia conference is also hosting the first meeting of the Human Proteome Organisation (HUPO). One of its founders, Ian Humphery-Smith, a professor at the University of Utrecht in the Netherlands, describes HUPO as an international effort to bring commercial and academic groups together to study the output of all human genes. Professing certainty that proteomics is "an ocean in which many can swim and possibly even help one another stay afloat," Humphery-Smith, who is also chief operating officer of the Dutch company Glaucus Proteomics, warns in an E-mail that the alternatives to cooperation are sabotage and self-interested competition.

Whence arises the sudden ferment in proteomics? Joshua LaBaer, director of the two-year-old Institute of Proteomics at Harvard Medical School and a member of HUPO's inaugural council, observes that genomics conferences have recently become "a bit of a scramble to figure out what the next step is, now that the genome ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies